Future biotherapeutics have the potential to reach the clinic faster than ever before. In this webinar, Berkeley Lights experts present a unique integrated platform that accelerates both the identification of promising candidates and the production of leading therapeutic molecules. The platform leverages a new antibody discovery workflow capable of finding rare antibodies against difficult targets by screening up to 100,000 cells in less than a week. Once a therapeutic candidate is found, the platform then streamlines the path to the clinic via an expanding suite of superior cell line development capabilities.
Topics to be covered
-Accelerating antibody discovery against difficult targets
-Streamlining clonal cell line development
Anupam Singhal earned his PhD from the University of British Columbia (UBC). Singhal has over 15 years of experience in nanotechnology and microfluidics at UBC, the University of Toronto, and Stanford University. His research has been cited more than 600 times and has resulted in several patents for molecular disease diagnosis, antibody discovery, and the development and production of cell lines for biologics. At Berkeley Lights, Singhal leads the development of next-generation platforms for antibody therapeutics discovery and development.
Renee Tobias
Director, Cell Line Development Product Management Berkeley Lights
Renee Tobias is a molecular biologist with 20 years of experience in the pharmaceutical and life science industries. Tobias spent the first part of her career in drug discovery research at various companies, including Amgen, Bayer, and DNAX/Schering-Plough, before leaving the bench to pursue commercial life science roles. As an applications scientist turned strategic marketer she has developed, commercialized, and supported a variety of complex analytical products for biopharmaceutical research and development. Currently, Tobias is the Director of Cell Line Development Product Management at Berkeley Lights, Inc., where she guides workflow product strategy for Beacon® cell line development.